Kassler-Taub Kenneth B.
SEC CIK 1885219 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | SVP, Regulatory, QA | 126.7K | — | — | 6 | 2022-02-28 | 2024-02-28 |
Most active insiders at LXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Artal Group S.A. | Dir, 10% | $2.00M | — |
| 2 | DEBBANE RAYMOND | Dir | $723.0K | — |
| 3 | Martens Rachel Yap | SVP, Partnerships, Corp Strat | — | — |
| 4 | Gopinathan Suma | SVP, Discovery | — | — |
| 5 | Artal Participations S.a r.l. | Dir, 10% | — | — |
| 6 | Cheung Ivan | Dir | — | — |
| 7 | Exton Michael | CEO, Dir | — | — |
| 8 | Sullivan Diane E. | Dir | — | — |
| 9 | McDermott Wendy | SVP, Human Resources | — | — |
| 10 | Granowitz Craig B | SVP, Chief Medical Off | — | — |
Kassler-Taub Kenneth B. made no open-market trades at LXRX in the last 12 months.
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-29 | 2024-02-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | M - OptEx | — | +67.4K | 126.7K | +114% | — |
| D | 2024-02-29 | 2024-02-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | F - Tax | $2.62 | -24.4K | 162.7K | -13% | -$63.8K |
| DM | 2023-03-01 | 2023-02-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | M - OptEx | — | +52.9K | 138.7K | +62% | — |
| D | 2023-03-01 | 2023-02-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | F - Tax | $2.17 | -19.1K | 119.6K | -14% | -$41.5K |
| DM | 2022-02-28 | 2022-02-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | M - OptEx | — | +36.6K | 99.1K | +59% | — |
| D | 2022-02-28 | 2022-02-28 | LXRX | LEXICON PHARMACEUTICALS, INC. | Kassler-Taub Kenneth B. | SVP, Regulatory, QA | F - Tax | $2.85 | -13.2K | 85.9K | -13% | -$37.7K |
Purchase Sale Sale after option exercise All abbreviations